Dornase
Health-related quality of life (HRQOL)
measurements provide valuable information about the psychological and
social impact of treatment on patients with cystic fibrosis (CF). This
study evaluated the HRQOL of Brazilian patients with CF and assessed the
changes in HRQOL domains over 1 year after dornase alfa (Pulmozyme)
introduction.One hundred fifty-six
stable patients with CF and 89 caregivers answered the
Portuguese-validated version of the Cystic Fibrosis
Questionnaire-Revised (CFQ-R) at baseline (T(0)), and at 3 (T(1)), 6
(T(2)), 9 (T(3)), and 12 (T(4)) months of follow-up. Eighteen patients
were excluded because they did not fulfill the inclusion criteria. The
patients were analyzed in two groups: those aged 6-11 years and those
aged 14 years and older. ANOVA for observed repeated results and the
last observation carried forward (LOCF) method for missing data were
used for the statistical analysis.
No comments:
Post a Comment